Unichem Laboratories Limited (UNICHEMLAB.NS)
INR 746.9
(-1.82%)
INR 746.9
(-1.82%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 931.91 Million INR | -28.48% |
| 2022 | 1.3 Billion INR | -45.7% |
| 2021 | 2.39 Billion INR | 476.37% |
| 2020 | 416.32 Million INR | 311.2% |
| 2019 | -197.12 Million INR | -852.72% |
| 2018 | 26.18 Million INR | 100.51% |
| 2017 | -5.15 Billion INR | -729.48% |
| 2016 | 819.22 Million INR | 417.33% |
| 2015 | 158.35 Million INR | 417.33% |
| 2014 | -49.9 Million INR | 81.14% |
| 2013 | -264.66 Million INR | -1191.09% |
| 2012 | 24.25 Million INR | -94.74% |
| 2011 | 461.42 Million INR | 32.36% |
| 2010 | 348.62 Million INR | 187.21% |
| 2009 | 121.38 Million INR | 126.4% |
| 2008 | 53.61 Million INR | -62.42% |
| 2007 | 142.66 Million INR | 1782.31% |
| 2006 | -8.48 Million INR | 98.51% |
| 2005 | -570.89 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | 1.86 Billion INR | 43.44% |
| 2023 Q4 | 931.91 Million INR | 40.91% |
| 2023 Q3 | 661.37 Million INR | -70.87% |
| 2023 FY | 931.91 Million INR | -28.48% |
| 2023 Q2 | 2.27 Billion INR | 21.47% |
| 2022 Q4 | 1.3 Billion INR | -61.69% |
| 2022 Q1 | 3.72 Billion INR | 55.35% |
| 2022 Q2 | -269.59 Million INR | -107.23% |
| 2022 FY | 1.3 Billion INR | -45.7% |
| 2022 Q3 | 3.4 Billion INR | 1361.59% |
| 2021 Q3 | 2.1 Billion INR | 31.19% |
| 2021 Q2 | 1.6 Billion INR | -48.88% |
| 2021 Q1 | 3.13 Billion INR | 653.96% |
| 2021 Q4 | 2.39 Billion INR | 13.99% |
| 2021 FY | 2.39 Billion INR | 476.37% |
| 2020 Q1 | 6.45 Billion INR | 3373.72% |
| 2020 FY | 416.32 Million INR | 311.2% |
| 2020 Q3 | 4.08 Billion INR | 3450.59% |
| 2020 Q2 | 115.17 Million INR | -98.22% |
| 2020 Q4 | 416.32 Million INR | -89.82% |
| 2019 Q3 | 7.88 Billion INR | 1031.83% |
| 2019 FY | -197.12 Million INR | -852.72% |
| 2019 Q4 | -197.12 Million INR | -102.5% |
| 2019 Q2 | -845.69 Million INR | -108.48% |
| 2019 Q1 | 9.97 Billion INR | 38001.34% |
| 2018 FY | 26.18 Million INR | 100.51% |
| 2018 Q4 | 26.18 Million INR | 0.0% |
| 2018 Q1 | 15.61 Billion INR | 402.83% |
| 2017 Q3 | -8.02 Billion INR | 0.0% |
| 2017 FY | -5.15 Billion INR | -729.48% |
| 2017 Q4 | -5.15 Billion INR | 35.77% |
| 2016 FY | 819.22 Million INR | 417.33% |
| 2016 Q4 | 819.22 Million INR | 0.0% |
| 2015 FY | 158.35 Million INR | 417.33% |
| 2014 FY | -49.9 Million INR | 81.14% |
| 2013 FY | -264.66 Million INR | -1191.09% |
| 2012 FY | 24.25 Million INR | -94.74% |
| 2011 FY | 461.42 Million INR | 32.36% |
| 2010 FY | 348.62 Million INR | 187.21% |
| 2009 FY | 121.38 Million INR | 126.4% |
| 2008 FY | 53.61 Million INR | -62.42% |
| 2007 FY | 142.66 Million INR | 1782.31% |
| 2006 FY | -8.48 Million INR | 98.51% |
| 2005 FY | -570.89 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 859.94 Million INR | -8.369% |
| Ind-Swift Limited | 9.5 Billion INR | 90.199% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 71.751% |
| Sakar Healthcare Limited | 790.93 Million INR | -17.824% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 74.767% |
| Innova Captab Limited | 2.33 Billion INR | 60.068% |
| Divi's Laboratories Limited | -39.77 Billion INR | 102.343% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 118.592% |
| Morepen Laboratories Limited | -231.17 Million INR | 503.123% |
| Mankind Pharma Limited | -1.74 Billion INR | 153.303% |
| Sequent Scientific Limited | 4.17 Billion INR | 77.698% |
| Wanbury Limited | 1.1 Billion INR | 15.73% |
| Laurus Labs Limited | 24.35 Billion INR | 96.174% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 84.865% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 132.783% |
| Alembic Limited | 66.9 Million INR | -1292.999% |
| Hikal Limited | 7.96 Billion INR | 88.303% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 75.894% |
| Neuland Laboratories Limited | -214.05 Million INR | 535.357% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 66.967% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 121.747% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 184.62% |
| Themis Medicare Limited | 764.96 Million INR | -21.825% |
| RPG Life Sciences Limited | -364.7 Million INR | 355.529% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 76.178% |
| Lupin Limited | 19.38 Billion INR | 95.193% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 474.576% |
| Wockhardt Limited | 18.27 Billion INR | 94.899% |
| Vaishali Pharma Limited | 119.13 Million INR | -682.235% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 64.32% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 167.048% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 96.558% |
| FDC Limited | -57.75 Million INR | 1713.651% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 92.783% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -676.344% |
| Eris Lifesciences Limited | 13.8 Billion INR | 93.25% |
| Venus Remedies Limited | -267.7 Million INR | 448.12% |
| ZIM Laboratories Limited | 983.6 Million INR | 5.255% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 180.494% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 354.247% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 116.92% |
| Shilpa Medicare Limited | 9.06 Billion INR | 89.725% |
| Albert David Limited | -278.36 Million INR | 434.777% |
| Ajanta Pharma Limited | -954.9 Million INR | 197.593% |
| Hester Biosciences Limited | 2.29 Billion INR | 59.318% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -542.807% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 90.71% |
| Gufic Biosciences Limited | 3.19 Billion INR | 70.826% |
| Windlas Biotech Limited | -273.04 Million INR | 441.311% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 139.69% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | -213.166% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 4.498% |
| Granules India Limited | 9.28 Billion INR | 89.965% |
| Aarti Drugs Limited | 5.54 Billion INR | 83.204% |
| Bal Pharma Limited | 1.26 Billion INR | 26.247% |
| Alkem Laboratories Limited | -1.6 Billion INR | 157.905% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 101.286% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 830.124% |
| Medicamen Biotech Limited | 160.31 Million INR | -481.299% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | -305.299% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 5152.131% |
| Valiant Laboratories Limited | 649.9 Million INR | -43.393% |
| Orchid Pharma Limited | -1.31 Billion INR | 170.93% |
| Medico Remedies Limited | 78.67 Million INR | -1084.483% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 122.439% |
| Ipca Laboratories Limited | 11.41 Billion INR | 91.836% |
| Brooks Laboratories Limited | 49.48 Million INR | -1783.229% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -1916.654% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.81% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 97.072% |
| NATCO Pharma Limited | -5.81 Billion INR | 116.021% |
| Suven Life Sciences Limited | -1.63 Billion INR | 157.078% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 51.787% |
| Strides Pharma Science Limited | 23.25 Billion INR | 95.993% |
| Indoco Remedies Limited | 6.47 Billion INR | 85.61% |
| Alpa Laboratories Limited | 35.36 Million INR | -2535.285% |
| Lasa Supergenerics Limited | 205.79 Million INR | -352.828% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 198.951% |